EA202191653A1 - CRYSTALLINE FORMS AND SALT FORMS OF KINASE INHIBITOR - Google Patents

CRYSTALLINE FORMS AND SALT FORMS OF KINASE INHIBITOR

Info

Publication number
EA202191653A1
EA202191653A1 EA202191653A EA202191653A EA202191653A1 EA 202191653 A1 EA202191653 A1 EA 202191653A1 EA 202191653 A EA202191653 A EA 202191653A EA 202191653 A EA202191653 A EA 202191653A EA 202191653 A1 EA202191653 A1 EA 202191653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
forms
relates
present
crystalline forms
kinase inhibitor
Prior art date
Application number
EA202191653A
Other languages
Russian (ru)
Inventor
Френель Диморин
Халид Шах
Сагар Шакья
Питер Вон
Кортни С. Джонсон
Мелани Джейнелл Бевилл
Стефан Д. Пэрент
Original Assignee
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. filed Critical Экселиксис, Инк.
Priority claimed from PCT/US2019/065972 external-priority patent/WO2020123800A1/en
Publication of EA202191653A1 publication Critical patent/EA202191653A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к кристаллическим формам свободного основания ингибитора c-Met, соединения 1. Настоящее изобретение также относится к кристаллическим формам солей соединения 1. Настоящее изобретение также относится к фармацевтическим композициям, содержащим твердые полиморфы свободного основания и соли соединения 1. Настоящее изобретение также относится к способам лечения заболевания, нарушения или синдрома, опосредованного, по меньшей мере частично, модулированием активности протеинкиназы in vivo.The present invention relates to crystalline forms of the free base of the c-Met inhibitor, compound 1. The present invention also relates to crystalline forms of salts of compound 1. The present invention also relates to pharmaceutical compositions containing solid polymorphs of the free base and salts of compound 1. The present invention also relates to methods of treating a disease, disorder, or syndrome mediated, at least in part, by modulating protein kinase activity in vivo.

EA202191653A 2019-06-03 2019-12-12 CRYSTALLINE FORMS AND SALT FORMS OF KINASE INHIBITOR EA202191653A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856469P 2019-06-03 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
EA202191653A1 true EA202191653A1 (en) 2021-10-20

Family

ID=78572615

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191653A EA202191653A1 (en) 2019-06-03 2019-12-12 CRYSTALLINE FORMS AND SALT FORMS OF KINASE INHIBITOR

Country Status (1)

Country Link
EA (1) EA202191653A1 (en)

Similar Documents

Publication Publication Date Title
PH12021551356A1 (en) Crystalline forms and salt forms of a kinase inhibitor
EA201792214A1 (en) COMPOUNDS OF SUBSTITUTE QUINAZOLINE
EA202091267A1 (en) 1,2,4-OXADIAZOLIC COMPOUNDS AS INHIBITORS OF CD47 SIGNAL PATHWAYS
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
EA202190086A1 (en) PCSK9 ANTAGONIST COMPOUNDS
MX2021014773A (en) Crystalline salt forms of a kinase inhibitor.
EA201690752A1 (en) INHIBITORS G12C KRAS
EA201991884A3 (en) G12C KRAS INHIBITORS
EA200702339A1 (en) SUBSTITUTED AMIDA DERIVATIVES AS AN INHIBITOR PROTEINKINASE INHIBITORS
EA200900152A1 (en) PYRROLOTRIAZINKINASE INHIBITORS
EA202190681A1 (en) DIMETHYLAMINOAZETIDINE AMIDES AS JAK INHIBITORS
EA201492170A1 (en) NEW CYPRIDE N-PYRIDINYLAMIDES SUBSTITUTED AS A KINAZ INHIBITOR
EA201991894A1 (en) PIPERIDINE-SUBSTITUTED Mnk INHIBITORS AND RELATED WAYS
EA202091773A1 (en) METHOD FOR MODULATION OF TIGIT AND PD-1 SIGNAL PATHWAYS USING 1,2,4-OXADIAZOL COMPOUNDS
EA200901474A1 (en) SALTS [4- (6-FLUOR-7-METYLAMINO-2,4-DIOXO-1,4-DIHYDRO-PLAIN-2-CHINAZOLIN-3-IL) -5-CHLORTHIOPHEN-2-ILSULPHONYLMOCHEVANIUM IN VARIOUS CRYSTAL-HEADPHONE-2-ILSULPHONYLMOCHEVAN IN VARIOUS CRYSTAL-4-ILSULPHONYLMOCHEVAN IN VARIOUS CRYSTAL-4-ILSULPHONYLMOCHEVANIUM ON THEIR BASIS
EA202192433A1 (en) COMPOUNDS USEFUL IN HIV THERAPY
EA202090959A1 (en) AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS, THEIR SALTS AND METHODS OF THEIR SYNTHESIS
EA201992744A1 (en) PHARMACEUTICAL COMPOSITIONS N- (2- (2- (DIMETHYLAMINO) ETOXY) -4-METOXY-5 - ((4- (1-METHYL-1H-INDOL-3-IL) PYRIMIDIN-2-IL) AMINO) Phenyl) Acrylamide AND HIS SALTS
EA202090040A1 (en) COMPOSITION FOR INJECTION
MX2023005273A (en) Pharmaceutical compositions of a kinase inhibitor.
HRP20210359T1 (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
EA201991095A1 (en) SUBSTITUTED NITROGEN CONTAINING COMPOUNDS
CY1123185T1 (en) INDOLE DERIVATIVES
EA202191653A1 (en) CRYSTALLINE FORMS AND SALT FORMS OF KINASE INHIBITOR
EA202192760A1 (en) TRICYCLIC COMPOUNDS